27-Feb-2026
IQVIA Releases its 2025 Sustainability Report
Business Wire (Fri, 27-Feb 4:47 PM ET)
IQVIA Holdings (IQV) Gets a Hold from Citi
TipRanks (Fri, 27-Feb 7:41 AM ET)
TipRanks (Thu, 26-Feb 9:50 AM ET)
Charles River Labs Breaks The Mold, Announces Bold Divestiture Plans
Benzinga (Wed, 25-Feb 9:06 AM ET)
IQVIA Expands End-to-End Drug Discovery Platform with Strategic Charles River Acquisition
Market Chameleon (Wed, 25-Feb 3:18 AM ET)
Charles River announces divestitures, updates guidance
Seeking Alpha News (Wed, 25-Feb 7:35 AM ET)
Business Wire (Wed, 25-Feb 7:00 AM ET)
Market Chameleon (Thu, 19-Feb 3:29 AM ET)
IQVIA to Speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day
Business Wire (Wed, 18-Feb 4:15 PM ET)
Business Wire (Tue, 10-Feb 8:00 AM ET)
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Iqvia Holdings trades on the NYSE stock market under the symbol IQV.
As of February 27, 2026, IQV stock price climbed to $178.81 with 4,513,390 million shares trading.
IQV has a beta of 1.04, meaning it tends to be more sensitive to market movements. IQV has a correlation of 0.15 to the broad based SPY ETF.
IQV has a market cap of $30.34 billion. This is considered a Large Cap stock.
Last quarter Iqvia Holdings reported $4 billion in Revenue and $3.42 earnings per share. This beat revenue expectation by $124 million and exceeded earnings estimates by $.13.
In the last 3 years, IQV traded as high as $261.73 and as low as $134.65.
The top ETF exchange traded funds that IQV belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
IQV has underperformed the market in the last year with a return of -4.1%, while the SPY ETF gained +18.5%. In the last 3 month period, IQV fell short of the market, returning -22.9%, while SPY returned +1.2%. However, in the most recent 2 weeks IQV has outperformed the stock market by returning +7.1%, while SPY returned +0.6%.
IQV support price is $164.80 and resistance is $176.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IQV shares will trade within this expected range on the day.